Key result
The GutHeart trial will randomize 150 patients with stable heart failure and reduced ejection fraction to rifaximin, Saccharomyces boulardii, or no treatment to evaluate changes in ejection fraction.
Why the study?
Does targeting the gut microbiota with rifaximin or Saccharomyces boulardii improve left ventricular ejection fraction in patients with stable HFrEF?
Population
150 patients with stable heart failure and a left ventricular ejection fraction <40%
Comparison
Antibiotic rifaximin or the probiotic yeast… vs No treatment (control)
Design
RCT, 1:1:1 fashion, open-label
Follow-up
3 months, with further follow-up at 6 months
Authors
Loading...
Rifaximin or Saccharomyces boulardii does not improve LVEF in stable HFrEF; challenges broad microbiome modulation and leaves open targeted interventions in future trials.
RCT (n=150)
Open-label
1:1:1
Yes
Does targeting the gut microbiota with rifaximin or Saccharomyces boulardii improve left ventricular ejection fraction in patients with stable HFrEF?
The GutHeart trial is designed to evaluate whether manipulating the gut microbiota with rifaximin or Saccharomyces boulardii improves left ventricular function in patients with stable HFrEF.
Mayerhofer et al. (2018) conducted an RCT in Heart failure with reduced ejection fraction (n=150). Rifaximin or Saccharomyces boulardii vs. No treatment was evaluated on Baseline-adjusted left ventricular ejection fraction as measured by echocardiography after 3 months. The GutHeart trial will randomize 150 patients with stable heart failure and reduced ejection fraction to rifaximin, Saccharomyces boulardii, or no treatment to evaluate changes in ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: